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Abstract
Background: Intraarticular corticosteroids (IACs) have been used to treat temporomandibular joint (TMJ) arthritis.
However, prospective clinical studies with magnetic resonance imaging (MRI) scoring are lacking. The aim of this
study was to examine efficacy and safety of a single IAC in the TMJ in adolescents with juvenile idiopathic arthritis
(JIA) in a clinical setting.
Methods: In this Norwegian prospective multicenter pilot study 15 patients with JIA (mostly persistent oligoarthritis or
RF negative polyarthritis categories) and a clinically and MRI-verified diagnosis of TMJ arthritis were treated with IACs
and followed for 2 years. Demographics, systemic medication, general disease activity and outcome measures were
recorded including a pain-index score and maximal incisal opening (MIO). Inflammation and bone damage scores
were assessed, using two recently published MRI scoring systems with masked radiological evaluation.
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Results: Among the 15 patients, 13 received a single IAC (5 bilateral), and 2 repeated IACs once unilaterally. Thus, the
total number of IACs was 22. Median age was 15 years and the majority had an age not thought of as critical regarding
mandibular growth retardation due to steroid injection. During the 2-year observation period systemic medication with
disease modifying antirheumatic drugs (DMARDs) including biologics was initiated or adjusted in 10/15 (67%) patients.
At the 2-months study visit after injection we observed a minimal improvement in MIO from median 44 (1st, 3rd
quartiles; 36, 48) mm to 45 (43, 47) mm, p = 0.045 and decreased MRI mean additive inflammatory score from 4.4 ± 1.8
standard deviations (SD) to 3.4 ± 2.0, p = 0.040. From baseline to the 2-months follow-up pain improved in 6/11
patients but pain scores were not significantly improved. MRI-assessed damage increased in two patients with
repeated IACs, and decreased in 3 patients but most of the patients were stable over the 2-year follow-up. Intra-rater
repeatability of the MRI scoring system domains varied from poor to excellent.
Conclusions: In this pilot study of predominately single IACs to the TMJ in combination with systemic treatment we
observed improvement in MRI-assessed inflammation, mostly stable condylar bone conditions and minimal clinical
improvement in adolescents with JIA and TMJ arthritis. No severe side effects were seen.
Keywords: Juvenile idiopathic arthritis, Temporomandibular joint, Intraarticular corticosteroids, Temporomandibular
arthritis, Magnetic resonance imaging, Efficacy, Adverse events
Background
The temporomandibular joint (TMJ) is one of the most
commonly involved joints in children with juvenile idio-
pathic arthritis (JIA), and may lead to impaired joint func-
tion, pain, growth impairment with dentofacial deformities
[1–4], a reduced posterior airway space with related comor-
bidities [5, 6], and impaired quality of life [7]. The rate of
TMJ arthritis varies significantly (40–90%) in different JIA-
cohorts using magnetic resonance imaging (MRI) [8–10],
as reviewed by Larheim et al. [11]. TMJ arthritis may
be clinically silent with symptoms and signs seen only late
in the disease course [3]. The diagnostic assessment is
therefore a particular challenge. The definition of JIA [12]
frequently cannot be applied to the TMJ [11].
Both systemic and local treatments have been used in
patients with TMJ arthritis [13–15]. Several observa-
tional studies report short-term effect of intraarticular
corticosteroid injections (IACs) to the TMJ on pain and
maximal incisal opening (MIO) [16–21]. It has also been
shown that the IACs can be safely performed by trained
specialists both with the “landmark guiding technique”
guided by anatomical landmarks, and with MRI, ultra-
sound or computed tomography (CT) guidance [17, 19,
22, 23]. However, treatment with IACs has been sus-
pected to inflict rather than improve mandibular growth
impairment [24, 25]. IACs to the TMJ may be performed
with or without lavage for example by the Alstergren
push-and-pull technique [26].
Retrospective studies with observation periods ranging
from mean 2 to 23 months show a highly variable rate of
improvement in MRI-assessed inflammation (18–83%)
in TMJs receiving IACs, most often with stable condylar
status on MRI [16, 17, 27–29]. However, according to
Stoustrup et al. [30] and Stoll et al. [31] studies on IACs
have a low level of evidence due to methodological
issues. The studies are mostly retrospective and single
center case-series, and the outcome assessors are not
masked regarding pre- or post-treatment assessments.
Randomized controlled trials are lacking, and systematic
prospective follow-up studies with validated clinical as-
sessments tools and imaging scoring systems are also
missing. To our knowledge, there are no prospective
studies with masked standardized MRI assessment ad-
dressing safety and efficacy of IACs in the TMJ in JIA.
Therefore, the aim of this Norwegian 2-year prospective
multicenter pilot study of adolescents with JIA and TMJ
arthritis was, by using validated clinical outcome mea-
sures and two newly published MRI scoring systems, to
assess efficacy and safety of single IACs in the TMJ in
terms of (i) reducing pain and improving maximal
mouth opening capacity, and (ii) reducing joint inflam-
mation and bone damage.
Material and methods
Study design and patients
This 2-year prospective multicenter-study of IACs in ad-
olescents with JIA and TMJ arthritis, is part of a larger
Norwegian prospective multicenter cohort on JIA (www.
norjia.com). The terminology adheres to TMJaw (earlier
EuroTMJoint) consensus-based standardized termin-
ology [32]. Clinical and demographic data were collected
between November 2015 and September 2019 at the De-
partment of Pediatrics, University Hospital North
Norway Tromsø, Public Dental Service Competence
Centre of North Norway, Tromsø, Haukeland University
Hospital Bergen, and Oslo University Hospital, Rikshos-
pitalet, Oslo.
Fifteen adolescents with JIA were consecutively re-
cruited and a total of 22 TMJ injections with corticoste-
roids were performed. No control group was included
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due to ethical reasons. TMJ arthritis was defined as
“clinical signs of pain on jaw movement, limitation of
MIO, limitation of laterotrusive- or protrusive jaw move-
ments or dentofacial growth disturbances and MRI signs
of TMJ-arthritis (i.e. active inflammation in the TMJ
based on increased contrast enhancement, bone marrow
edema and/or effusion)”. Inclusion criteria were patients
fulfilling the JIA diagnosis according to the classification
criteria defined by the International League of Associa-
tions for Rheumatology (ILAR), age < 18 years, and arth-
ritis in one or both TMJs. Exclusion criteria were
contraindications to MRI such as cardiac pacemaker,
metallic clips, contrast allergy etc. or previous TMJ IACs
within the last 3 years. Non-invasive management in
terms of physiotherapy and splint devices were consid-
ered and used by most adolescents in the study without
sufficient effect before the decision to perform IACs was
taken.
The included patients had a clinical examination and a
MRI at baseline of the study before the TMJ IACs were
performed, and at follow-up visits after 1–3 months, 1
year and 2 years.
Clinical variables, TMJ examination, and assessment of
disease activity
Demographics, systemic medication, JIA category, dis-
ease onset and course type of JIA, medication, and a
general clinical examination including number of joints
with active arthritis, were registered by specialists in
pediatric rheumatology at each study visit. The physician
global evaluation of overall disease activity on a 10-cm
visual analogue scale (VAS) (MDgloVAS) was also
assessed at the visit. The specialists were calibrated by
thorough discussions of all study variables assessed in
the NorJIA study and the present NorJIA TMJ injection
substudy. Patient-reported global assessment of overall
well-being (PRgloVAS) and patient-reported pain
(PRpainVAS) within the last week on a 10-cm VAS were
also collected. On these scales, 0 indicates no disease ac-
tivity/no pain/best overall well-being, and 10 indicate
the maximum disease activity/worst pain/poorest overall
well-being, respectively [33]. Number of active joints
other than the TMJ was defined according to the clinical
definition of arthritis: swelling within a joint or limita-
tion in the range of joint movement with joint pain or
tenderness [34].
Clinical TMJ examination was performed by either a
specialist in oral and maxillofacial surgery or a specialist
in pediatric dentistry (PF, AR, JRB, JH) according to the
DC / TMD examination and diagnostics protocol [35]
and EuroTMJoint Clinical Recommendations protocol
[36]. The two examiners were calibrated repeatedly dur-
ing the study period [37]. The TMJ clinical outcomes for
this study were: 1, Pain-index score (i.e. pain frequency
last 2 weeks x pain intensity last 2 weeks (VAS 0–10))
scored by the patient, 2, Maximal incisal opening (MIO)
in mm scored by the clinical TMJ examiner and 3, jaw
function the last 2 weeks (VAS 0–10) scored by the pa-
tient was registered.
A routine complete blood cell count, erythrocyte sedi-
mentation rate (ESR) (mm/hour), and C-reactive protein
(CRP) (< 5 mg/l was set as 0) was obtained. Rheumatoid
factor (RF) immunoglobulin M was analyzed twice more
than 3months apart. The composite juvenile arthritis
disease activity score (JADAS10, range from 0 to 40) was
assessed, based on the MDgloVAS (range 0–10), PRglo-
VAS (range 0–10), active joint count (maximum 10
joints), and the ESR (normalized to 0–10, < 10mm/h
was set as 0) [33, 38]. Disease status was defined as ei-
ther active disease, inactive disease, clinical remission on
medication, or clinical remission off medication accord-
ing to the ACR provisional criteria [39]; inactive disease
requiring all the following: 1, no active joints; 2, no fever,
rash, serositis, splenomegaly or generalized lymphaden-
opathy attributable to JIA; 3, no active uveitis; 4, normal
ESR or CRP; 5, MDgloVAS =0; and 6, duration of morn-
ing stiffness of ≤15 min. Side effects were assessed and
registered as per protocol at each study visit, including
any signs of infection, bleeding, skin atrophy, facial palsy,
or intraarticular calcifications on MRI.
MRI method and outcomes
Fifty-seven examinations were obtained on either 3-T-
units (Magnetom Skyra, Siemens Healthcare, Erlangen,
Germany) using a 64-channel head/neck coil (n = 50) or
a 1.5-T-unit (Magnetom Aera or Avanto, Siemens
Healthcare, Erlangen, Germany) using 4-channel special
purpose coils (n = 7), according to protocol A or B, re-
spectively. As a minimum the protocols included water-
sensitive images, pre- and post-contrast T1-weighted im-
ages and one sequence with the mouth in the open pos-
ition. Details are provided in Supplementary Table 1.
One examination had susceptibility artefact-reducing se-
quences (WARP). The contrast medium given was 0.2
mL/kg (0.1 mmol/kg) body weight gadoterate meglumine
(Dotarem, Guerbet, Paris, France). None of the patients
needed sedation. All examinations were reviewed on a
PACS workstation (IDS7, Sectra Medical Systems, Lin-
köping, Sweden) in consensus between two experienced
specialists in radiology (TAL, TAA) at random order,
masked for personal data, injection laterality and time
point. One examination from each subject was randomly
selected for a second reading after an interval of ap-
proximately 3 months, to assess intra-rater variability.
Inter-rater variability was not assessed in this study.
The image outcomes were based on inflammation and
bone damage according to the two newly published MRI
scoring systems for evaluating TMJ arthritis as described
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by Tolend et al. [40, 41] and Kellenberger and Lochbuh-
ler et al. [25, 42]. The scoring systems were thoroughly
discussed between the radiologists before the reading
session. Total scores ranged from 0 to 8 for the Additive
inflammatory domain (bone marrow edema (absent/
present 0/1), bone marrow enhancement (absent/present
0/1), joint effusion (absent/small/large 0/1/2), synovial
thickening (absent/mild/moderate, severe 0/1/2), joint
enhancement (absent/mild/moderate, severe 0/1/2)) and
0–5 in the Additive damage domain (condylar flattening
(absent/mild/moderate, severe 0/1/2), erosions (absent/
mild/moderate, severe 0/1/2), disc abnormalities (ab-
sent/present 0/1)), and 0–4 in the Progressive scoring
system: Progressive inflammation (no inflammation/
mild/ moderate/severe/pannus 0/1/2/3/4) and Progres-
sive osseous deformity (normal/mild/moderate/ severe/
destruction 0/1/2/3/4). The scores were set as missing if
the images were not of sufficient quality due to braces
or other artefacts. In case of bilateral injection, the joint
with the most severe inflammation/bone damage was
chosen for statistical analysis.
Injection procedure
The preauricular skin was disinfected with 70% ethanol
and 5% chlorhexidine, before local anesthesia with an
auriculotemporal nerve block was applied. The push-
and-pull technique, and the amount of recovered syn-
ovial fluid in each sample was quantified with the hydro-
xocobalamin method, as described by Alstergren et al.
[26, 43]. A washing solution consisting of 22% hydroxo-
cobalamin (Behepan® 1 mg/ml) in physiological saline
(sodium chloride 9 mg/ml) was used. The TMJ was
injected with a total of 4 ml washing solution through a
stop-cock syringe. One milliliter of washing solution was
injected slowly, the valve was turned and then as much
fluid as possible was aspirated back. This procedure was
repeated a total of three times for each joint leaving the
same cannula inside the joint. If aspiration of the wash-
ing solution was possible and the resistance in the syr-
inge was minor during injection, then the needle tip was
considered to be placed within the joint space. After
sampling of synovial fluid from the upper joint compart-
ment, steroids were injected according to the landmark
guiding technique, 1 cm anterior and 2mm inferior to
the tragus of the ear. Two different types of steroids
were used: methylprednisolone acetate (Depomedrol®)
and triamcinolone hexacetonide (Lederspan®). Methyl-
prednisolone acetate was used in one of the first patients
because this was used by Alstergren et al. in their studies
on the push-and-pull technique to the TMJ. Shortly after
start of the study we agreed to use solely triamcinolone
hexacetenoide [26]. The following dosages were set: pa-
tients > 30 kg: 0.4 ml triamcinolone hexacetonide 20mg/
ml and children < 30 kg: individual dosage. In 15 TMJs a
syringe of 25G 0.5 × 25 mm and in 7 TMJs a syringe of
23G 0.6 × 30mm was used for the injection. The injec-
tion procedure was performed by experienced specialists
in oral and maxillofacial surgery at all centers (PF, AR,
JRB). The results of the synovial fluid analyses will be
published in a separate paper.
Statistical analyses
For description of clinical and demographic data, median
(1st, 3rd quartiles), mean (standard deviations (SD)) and
frequencies (percentage) were used as appropriate. For
the not normally distributed data of MRI-scoring mean
(SD) was used for more informative description of the
values. Multiple testing of four time-points and Bonfer-
roni correction for 6 comparisons with a p-value < 0.008
was analyzed and considered, but found to be less in-
formative than testing for two time-points; with differ-
ences between baseline and 2-months, and 2-year
follow-up because of some missing data at different
follow-up time-points, varying number of follow-up
visits from 2 to 4, together with the low number of par-
ticipants. Based on previous studies [16, 17, 27–29] and
clinical experience we chose to assess change in clinical
parameters (MIO and pain index) and change in the
MRI inflammatory scores mainly between baseline and
2-months, while change in MRI osseous deformities and
damage scores was assessed between baseline and 2-year
follow-up.
When testing continuous data for differences between
baseline and 2-months, and 2-year follow-up, the Wil-
coxon signed-rank test was used for not normally dis-
tributed data. For nominal data tested for differences
between baseline and 2-months, and 2-year follow-up
McNemar Chi-square test was used, and for ordinal data
Wilcoxon signed-rank test. A p-value < 0.05 was consid-
ered statistically significant. For description of outcome
after receiving IACs at the different time-points in Fig. 1,
percentage of patients were used for absolute improve-
ment of the variables pain, MIO and MRI. For the MRI
assessment, the intra-observer consensus agreement for
the MRI-scoring was assessed with Cohen’s kappa: poor
(0.01–0.20), fair (0.21–0.40), moderate (0.41–0.60), sub-
stantial (0.61–0.80) and almost perfect (0.81–1.00)
agreement. Statistical analysis was performed using SPSS
software, versions 25 or 26.
Results
Demographic and disease activity parameters
Demographic and disease activity characteristics at base-
line are given in Table 1. In total 15 adolescents were in-
cluded and 22 TMJ injections were performed in this
study. Among the 15, 80% were female and the median
(quartiles) age at baseline was 15 (1st, 3rd quartiles 11,
16) years. The majority of adolescents belonged to the
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persistent oligoarthritis (6/15; 40%) or the RF negative
polyarthritis (5/15; 33%) JIA categories. Five patients
(33%) received bilateral TMJ IACs. Two patients (13%)
had repeated injections once unilaterally 11 and 13
months after baseline, on indication pain and ongoing
MRI-assessed inflammation. Ten of 22 TMJs were sam-
pled with the push-and-pull method (46%). Follow-up
visits were performed at a median of 2.0 (1.8, 3.3)
months (n = 14), 12.0 (11.0, 13.0) months (n = 15), and
22.0 (22.0, 23.0) months (n = 11) after TMJ injections at
baseline. All patients had active disease at baseline. At
the 2-year follow-up five of 11 (46%) patients were in
remission either on or off medication. During the 2-year
follow-up period 10/15 (67%) changed or increased their
systemic medication with DMARDs and biologics. From
participant centers, two patients were included in Oslo,
one patient in Bergen and 12 patients in Tromsø.
Clinical outcomes
Among the clinical TMJ parameters pain-index score
changed from median 6.0 (0.0–13.0) at baseline to 2.0
(0.0–10.0) at 2-months follow-up, this was not a statisti-
cally significant improvement (p = 0.263). There was a
minimal, but statistically significant increase in MIO
during the same observation period (p = 0.045) (Table 2).
At 2-year follow-up, scores for pain and jaw function
improved from baseline in terms of pain frequency (p =
0.016), pain intensity (p = 0.012), VAS jaw function (p =
0.034), and pain-index score (p = 0.012) (Table 2).
Absolute improvement in pain-index was seen in 6/11
(55%) of the patients at 2-months follow-up, 9/13 (69%)
of the patients at 1-year follow-up and 8/10 (80%) of the
patients at 2-year follow-up (Fig. 1). Two of 11 patients
(18%) had increased pain and 3 (27%) unchanged pain
from baseline to 2-months follow-up. At 2-year follow-
up 2 of 10 patients (20%) had a stable pain-index score
of zero, and none of the patients had increased pain-
index compared to baseline. Absolute improvements in
MIO at the three follow-up visits were 9 of 13 (69%), 10
of 13 (77%) and 9 of 11 (82%) respectively (Fig. 1). In 3
of 13 patients (23%) MIO decreased at 2-months follow-
up (48 to 42mm, 46 to 45mm, 45 to 44mm respect-
ively). In 2 of 11 patients (18%) MIO decreased (40 to
37mm, 49 to 45mm respectively) between baseline and
2-year follow-up. Improvements in MIO ≥5 mm at the
three follow-up visits were 4 of 13 (31%), 6 of 13 (46%)
and 5 of 11 (46%) respectively.
MRI outcomes
There was a statistically significant reduction in the addi-
tive inflammatory domain from baseline to the 2-months-
and from baseline to the 2-year follow-up, (p = 0.040, p =
0.017 respectively) (Table 3) (Fig. 1). At the 2-months
follow-up, 6 of 13 patients (46%) had lower score as shown
in Fig. 1, while 6 (46%) had unchanged and 1 (8%) had
higher score in the additive inflammatory score. Among
the 10 patients at 2-year follow-up, 7 (70%) had lower
score, while 3 (30%) remained unchanged. The MRIs at
baseline and at follow-up 2months after IAC in one of the
patients with improvement of temporomandibular joint
enhancement is shown in Fig. 2.
There was no statistically significant change in the
mean progressive inflammation score between baseline
and 2-months follow-up; 4 of 13 (31%) had lower score,
Fig. 1 Percentage of patients with improvement. Percentage of adolescents with juvenile idiopathic arthritis (JIA) and temporomandibular joint
(TMJ) arthritis with improvement in Pain index, maximal incisal opening (MIO) and magnetic resonance imaging (MRI) inflammatory additive
domain score, damage additive domain score, progressive inflammation score, progressive osseous deformity score, in the time interval between
baseline and follow-up visits (FU) after receiving intraarticular corticosteroids (IACs)
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and 9 of 13 (46%) had unchanged score. At the 2-year
follow-up; 5 of 11 patients (46%) had lower score and 6
(55%) was unchanged compared to baseline.
No statistically significant change was seen in the two
bone damage scores. In the mean additive damage do-
main, 2 of 14 (14%) had lower score, 9 (64%) unchanged
and 3 (21%) had increased score at 2-months follow-up.
At 2-year follow-up 2 of 10 (20%) had lower score, 6
(60%) was unchanged and 2 (20%) had higher score. The
MRIs at baseline and at follow-up 2 years after IAC and
systemic treatment show aggravation of bone damage in
one patient (Case 10) and improvement in case 9 as
shown in Fig. 3. In the mean progressive osseous de-
formity score at the 2-months follow-up, 2 of 14 (14%)
had a lower score, 11 (79%) had unchanged score, and 1
(7%) had higher score. At the 2-year follow-up 1 of 11
(9%) had lower score, 9 (82%) was unchanged, 1 (9%)
had higher score.
MRI score intra-observer agreement
For the additive inflammatory domain, the intra-
observer agreement between the readings was poor for
bone marrow edema and bone marrow enhancement
(negative kappa values), fair and moderate for joint effu-
sion (kappa values 0.38 and 0.46), substantial and almost
perfect for synovial thickening (0.63 and 0.90) and
moderate and poor for joint enhancement (0.41 and
0.00) for the right and left side, respectively. The cor-
responding value for the progressive inflammation
and progressive osseous deformity score was moderate
and poor (0.49 and 0.20) and moderate (0.52 and
0.58). For the additive osseous domain, the intra-
observer agreement was moderate to substantial for
flattening (0.48 and 0.74), fair and moderate for ero-
sions (0.36 and 0.44) and fair and almost perfect for
disc abnormalities (0.36 and 0.84).
Side effects
No severe adverse events that could be related to the
IACs were reported, and there was no finding of intraar-
ticular calcifications on MRI. One of the adolescents ex-
perienced pain after the injection but this minor side
effect resolved within 1 month. Increased additive dam-
age domain score was seen in 2/10 (20%) and 1/11 (9%)
had increased progressive osseous deformity score in the
TMJ between baseline and 2-year follow-up. Both pa-
tients had ongoing MRI-assessed inflammation at 2-year
follow-up and repeated IACs 11 and 13 months respect-
ively after baseline. Among these one had lower pain
index and the other one unchanged (=0), and both pa-
tients had increased MIO at the 2-year follow-up. Fur-
thermore, two patients with only 1-year follow-up (cases
1 and 5) had increased scores according to additive dam-
age domain and progressive osseous deformity, together
Table 1 Characteristics at baseline in adolescents with JIA (n= 15)
receiving IACs to the TMJs (n= 22)
Baseline characteristic Value
Female, no. (%) 12 (80)
Age at injections, yrs 15 (11, 16)
Age at JIA onset, yrs. 11 (8, 14)
Disease duration, yrs. 1 (0, 5)
JIA-category, no (%)
Oligoarthritis persistent 6 (40)
Polyarthritis RF negative 5 (33)
Oligoarthritis extended 3 (20)
Enthesitis related arthritis 1 (7)
Disease activity, no (%)a
Active 15 (100)
Remission on medication –
Remission off medication –
Medication baseline, no (%)
No DMARDs 6 (40)
DMARDs (MTX) 3 (20)
Biologics combination 6 (40)
Disease activity variables
JADAS10 baseline (n = 8) 15.8 (12.9, 49.1)
No.of active joints (n = 14) 2.0 (1.0, 3.0)
PRpainVAS (n = 10) 4.8 (3.3, 7.6)
PRgloVAS (n = 10) 5.5 (3.3, 7.1)
MDgloVAS (n = 12) 2.5 (1.6, 4.5)
ESR (mm/h) (n = 12) 6.5 (3.5, 10.5)
TMJ-examination to injection, days 14.0 (1.0, 68.0)
Follow-up, months 22.0 (16.0, 23.0)
Injection to 2-months follow-up, (n = 14) 2.0 (1.8, 3.3)
Injection to 1-year follow-up, months (n = 15) 12.0 (11.0, 13.0)
Injection to 2-year follow-up, months (n = 11) 22.0 (22.0, 23.0)
Triamcinolone hexacetonide, dose, mg (n = 14) 20.0 (9.5, 20.0)
Methylprednisolone acetate, dose, mg (n = 1) 40.0 (n = 1)
Push-pull technique / No. TMJs (%) 10/22 (46)
Needle length, mm/ No. TMJs 25 mm/15, 30 mm/7
Data are median (1st, 3rd quartile) unless otherwise indicated. Two patients
received repeated injection on the same side, five patients received
bilateral injection
IACs intraarticular corticosteroid injection, JIA juvenile idiopathic arthritis, TMJ
temporomandibular joint, PRpainVAS patient reported pain visual analogue
scale, PRgloVAS patient reported global assessment of well-being, MDgloVAS
medical doctor global assessment of well-being, JADAS10 the composite
juvenile arthritis10-joint disease activity score, ESR erythrocyte sedimentation
rate, MTX methotrexate, DMARDs disease modifying antirheumatic drugs
adisease activity status according to the ACR provisional remission criteria [39]
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with ongoing inflammation (Table 4). Also, case 1 had a
trauma to the mandible, a blow against one of the con-
dyles, in between the 2-month and the 1-year follow-ups.
One of the patients, case 7, improved according to the
progressive osseous deformity from score 1 at the 2-
months follow-up to score 0 at the 2-year follow-up. Man-
dibular growth was not evaluated because the adolescents
in this study had mostly finished their growth at time for
TMJ injection: median age 15.0 (11.0, 16.0) years.
Discussion
To our knowledge, this is the first prospective study
using two recently published MRI scoring systems to as-
sess the efficacy and safety of IACs in the TMJ in adoles-
cents with JIA. We found that a single IAC in
combination with systemic therapy may improve short-
term and long-term MRI-assessed inflammation and
MIO, even though pain and MRI-assessed damage did
not improve significantly.
Clinical outcomes: pain and MIO
In our study the pain-index score improved in 6/11 pa-
tients at 2-months follow-up and 8/10 patients at the 2-
year follow-up median 22months after IACs to the
TMJs. Pain was one of the main indications for perform-
ing the IACs in our study, and the pain-index score is
reported to be a valid and sensitive outcome measure in
TMJ arthritis [18]. Improvement in pain is reported in
most retrospective studies in JIA children based on med-
ical chart information or the patients’ self-assessment of
pain, where improvement in orofacial symptoms is seen
in 67–100%, follow-up ranging from mean 3 to 52
months after TMJ-IACs [16, 23, 28, 44, 45]. However,
none of these studies used quantified pain reports.
Table 2 Disease activity and TMJ clinical measures during 2-year follow-up in 15 adolescents with JIA and TMJ-arthritis receiving
IACs
Pre- injection (T0) 2-months FU (T1) 1-year FU (T2) 2-year FU (T3) p-value T0-T1
Median months after IACs 0 2.0 (1.8, 3.3) 12.0 (11.0, 13.0) 22.0 (22.0, 23.0)
(1st, 3rd quartile) n = 15 n = 14 n = 15 n = 11
Disease activity, no (%)**
Active 15 (100) 7 (54) n = 13 10 (77) n = 13 6 (55)
Remission on medication – 2 (15) n = 13 2 (15) n = 13 2 (18)
Remission off medication – 4 (31) n = 13 1 (8) n = 13 3 (27)
Medication ***
No DMARDs, no (%) 6 (40) 5 (39) n = 13 4 (27) 3 (27) 0.317 a
DMARDs (MTX), no (%) 3 (20) 2 (15) n = 13 3 (20) 3 (27)
Biologics comb, no (%) 6 (40) 6 (46) n = 13 8 (53) 5 (46)
Disease activity measures
JADAS10 15.8 (12.9, 49.1) n = 8 11.0 (6.0, 20.0) n = 7 12.5 (6.8, 14.5) n = 9 8.5 (3.3, 15.3) n = 4 0.273b
No.of active joints 2.0 (1.0, 3.0) n = 14 0.0 (0.0, 2.0) n = 13 1.0 (0.0, 1.5) n = 13 0.0 (0.0, 1.0) n = 10 0.076b
ESR (mm/h) 6.5 (3.5, 10.5) n = 12 6.0 (3.8, 11.0) n = 10 5.0 (3.0, 7.0) n = 11 5.5 (3.8, 7.3) n = 10 0.445b
PRpainVAS 4.8 (3.3, 7.6) n = 10 3.5 (0.0, 5.8) n = 8 3.8 (1.6, 6.3) n = 10 1.5 (0.0, 4.5) n = 4 0.500b
PRgloVAS 5.5 (3.3, 7.1) n = 10 3.5 (0.1, 5.8) n = 8 4.0 (1.6, 5.1) n = 10 0.5 (0.0, 4.0) n = 4 0.345b
MDgloVAS 2.5 (1.6, 4.5) n = 12 0.5 (0.0, 4.0) n = 10 1.5 (0.1, 2.8) n = 12 0.0 (0.0, 1.0) n = 7 0.207b
TMJ activity measures
Pain frequency 2.0 (0.0, 4.0) 1.0 (0.0, 2.0) n = 11 1.0 (0.0, 2.0) n = 13 0.0 (0.0, 2.0) n = 10 0.245b
VAS pain intensity 3.0 (0.0, 6.5) n = 15 2.0 (0.0, 4.5) n = 11 2.0 (0.0, 3.5) n = 13 0.0 (0.0, 2.1) n = 10 0.292b
VAS jaw function 3.0 (0.0, 4.3) n = 13 0.0 (0.0, 2.4) n = 10 0.0 (0.0, 0.0) n = 13 0.0 (0.0, 2.8) n = 9 0.201b
Pain indexγ 6.0 (0.0, 13.0) n = 15 2.0 (0.0, 10.0) n = 11 2.0 (0.0, 8.5) n = 13 0.0 (0.0, 5.3) n = 10 0.263b
MIO (mm) 44 (36, 48) n = 15 45 (43, 47) n = 13 45 (42, 49) n = 13 46 (45, 48) n = 11 0.045b
Data are median (1st, 3rd quartiles) unless indicated otherwise. aMcNemar chi square test, bWilcoxon signed-rank test, *p ≤ 0.05 for statistical significance **
remission, status according to the ACR provisional remission criteria [39]***No DMARDs, Current us of NSAIDs and/or IACs; DMARDs, current use alone of MTX;
Biologics comb, current use of Biologics alone or in combination with MTX; γ Pain index = Pain frequency last 2 weeks x Pain intensity last 2 weeks (VAS 0–10); JIA
juvenile idiopathic arthritis, TMJ temporo-mandibular joint, LOM limited range on motion, VAS visual analogue scale, MTX methotrexate, DMARDs disease
modifying antirheumatic drugs, PRpainVAS patient reported pain visual analogue scale, PRgloVAS Patient reported global assessment of well-being, MDgloVAS
medical doctor global assessment of well-being, JADAS10 The composite juvenile arthritis 10-joint disease activity score, IACs intraarticular corticosteroid injections,
ESR erythrocyte sedimentation rate, MIO maximal incisal opening, FU follow-up
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Stoustrup et al. used the validated pain-index score in 13
JIA children receiving IACs to the TMJs in a prospective
pilot study [18]. They found significant short-term pain
reduction, but remitting pain at long-term follow-up, in-
dicating a loss of the initial effect of the IACs [18]. Our
study shows a trend for improvement in pain at the 2-
month follow-up, which is sustained during the observa-
tion period over 2 years (not statistically significant). The
sustained tendency of reduced pain may be due to the
systemic medication (DMARDs and biologics), which was
changed in 10/15 patients in our study. Five of the 11 pa-
tients were in remission at the 2-year follow-up, indicating
an effect of the treatment, which included IACs and the
systemic medication. The sampling procedure with lavage
may also induce improvement, Olsen-Bergem et al. found
that arthrocentesis with lavage in patients with TMJ arth-
ritis and JIA might be beneficial for the treatment out-
come, and that steroids did not add additional effect to
Table 3 Additive and progressive scoring system for assessment of inflammation and damage in the temporomandibular joint
(TMJ) by magnetic resonance imaging (MRI) in 15 adolescents with juvenile idiopathic arthritis (JIA) and TMJ-arthritis receiving
intraarticular corticosteroids (IACs)
Pre- injection (T0) 2- months FU (T1) 1-year FU (T2) 2-year FU (T3) p-value
Mean months after IACs (SD) 0
n = 15
2.4 ± 1.6
n = 14
12.3 ± 1.5
n = 15
21.5 ± 2.6
n = 11
Additive Inflammatory domain:
(Bone marrow edema,
bone marrow enhancement,
Joint effusion, Synovial
thickening, Joint enhancement)
4.4 ± 1.8 3.4 ± 2.0 n = 13 3.6 ± 1.7 n = 14 2.3 ± 1.7 n = 10 0.040* a
Bone marrow edema 0.3 ± 0.5 0.1 ± 0.3 0.1 ± 0.4 n = 14 0.0 ± 0.0 n = 10 0.500* b
Bone marrow enhancement 0.4 ± 0.5 0.2 ± 0.4 n = 13 0.1 ± 0.4 n = 14 0.0 ± 0.0 n = 11 0.250* b
Joint effusion 0.8 ± 0.9 0.7 ± 0.8 n = 14 0.6 ± 0.9 n = 14 0.3 ± 0.7 n = 10 0.705* a
Synovial thickening 1.0 ± 0.8 1.0 ± 0.8 n = 14 1.0 ± 0.8 n = 14 0.7 ± 0.8 n = 10 1.000* a
Joint enhancement 1.9 ± 0.3 1.5 ± 0.7 n = 13 1.8 ± 0.4 n = 14 1.3 ± 0.6 n = 11 0.059* a
Additive Damage domain:
(Condylar flattening,
erosions, disc abnormalities)
2.6 ± 1.5 2.8 ± 1.5 n = 14 2.7 ± 1.6 2.5 ± 1.7 n = 10 1.000** a
Condylar flattening 1.3 ± 0.9 1.6 ± 0.8 n = 14 1.5 ± 0.9 1.5 ± 0.9 n = 11 0.157** a
Erosions 0.6 ± 0.7 0.6 ± 0.8 n = 14 0.5 ± 0.8 0.4 ± 0.7 n = 10 0.655** a
Disc abnormalities 0.7 ± 0.5 0.6 ± 0.5 n = 14 0.7 ± 0.5 0.7 ± 0.5 n = 11 1.000** b
Progressive inflammation 2.6 ± 0.8 2.0 ± 1.1 n = 13 2.5 ± 1.0 n = 14 1.5 ± 0.9 n = 11 0.066* a
Progressive osseous deformity 2.0 ± 1.3 2.1 ± 1.1 n = 14 2.0 ± 1.4 2.0 ± 1.3 n = 11 1.000** a
Values are the mean ± SD unless indicated otherwise. N = 15 unless indicated otherwise. aWilcoxon signed-rank test. bMcNemar chi square test. *P ≤ 0.05 considered
statistically significant between T0-T1 and ** between T0-T3. Each joint is scored independently (the worst joint is chosen when bilateral injection), with possible total
scores ranging from 0 to 8 in the Additive inflammatory scoring system and 0–5 in the Additative damage domain, and 0–4 in the Progressive scoring system according
to (Tolend et al.) [40] and (Kellenberger et al.) [41]; 2 patients received repeated injection on the same side, 5 patients received bilateral injection
Fig. 2 MRI improvement of the inflammation. Oblique sagittal contrast enhanced T1 TSE images with fat suppression of a 16-year-old girl (case 8)
(a) at baseline with increased temporomandibular joint enhancement (blue arrow) and (b) at 2 months follow-up after IAC and no DMARDs with
complete regression of joint enhancement (blue arrow). Note also the disrupted disc and flattened condyle in both images
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the outcome [46]. The natural fluctuation with waxing
and waning disease activity over time often seen in JIA
must also be considered [47].
In line with most studies on treatment efficacy in JIA
we did not have improvement in all the cases receiving
TMJ IACs, 2/11 did not have improvement in pain and
3/11 had unchanged pain and 3/13 did not have im-
provement in MIO at 2 months follow-up as detailed in
Table 4.
We found that MIO improved in 9 of 13 patients at 2-
months follow-up, and in 9 of 11 patients between base-
line and 2-year follow-up after IACs to the TMJs. This is
similar to retrospective studies where improvements in
MIO are reported between 2.7 and 6.6 mm [16–19, 23,
28, 44, 45]. However, measurements of MIO are associ-
ated with much variation [48, 49], increase with age, and
show a wide normal range in children of the same age
[50]. In our study we used standardized protocols and
calibration of the examiners in order to avoid measure-
ment bias [35, 36]. Stoustrup et al. found the smallest
detectable difference in repeated MIO measurements in
patients with JIA to be 5 mm when a strict and standard-
ized measurement protocol with repeated measurements
were applied [49]. A clinically relevant improvement ≥5
mm was found in our study in 4 of 13 patients between
baseline and 2-months follow-up and in 5 of 11 between
baseline and 2-year follow-up after IACs. Our median
improvement in MIO may be influenced by random
error within the measurement procedure. Moreover,
MIO at baseline was not severely reduced, and we doubt
that this small change in MIO is a clinically relevant ef-
fect on jaw function even if statistically significant.
MRI outcomes
MRI-verified TMJ-arthritis is not always accompanied
by clinical symptoms from the TMJ.
A systematic review concluded that no single clinical
finding could accurately predict MRI findings consistent
with arthritis [51]. The measurements in our study
therefore included both standardized clinical assessment
tools with pain reports, MIO, and MRI to verify TMJ-
arthritis both at both baseline and follow-up.
A problem in evaluating outcome after IACs has
been the use of qualitative assessments and lack of
consistent definitions and MRI-scoring systems [40,
41]. In the assessment of inflammation in our study,
the additive inflammatory domain improved signifi-
cantly between baseline and the 2-months follow-up.
Improvement was seen in 6/13 patients as compared
to 4/13 patients in the progressive inflammation
score. At the 2-year follow-up, 7 of the 10 patients
improved significantly in the additive inflammatory
domain and 3 were stable, whereas in the progressive
inflammation score 5 of 11 patients improved at 2-
Fig. 3 MRI changes of the bone condition. Oblique sagittal pre- and
postcontrast T1 TSE images with fat suppression of the left TMJ of a
16-year-old girl (case 10) without improvement in inflammation:
joint enhancement is only minimally reduced from baseline (a, b) to
2-months after IAC (c, d). She was under MTX treatment. At 2-year
follow up, with a repeated injection 11months after baseline, there
is some reduction in joint enhancement (blue arrow), but the disc
has become perforated and the condylar surface discretely more
flattened and irregular (red arrow) (e, f). Oblique sagittal T1 TSE
images with fat suppression of the right TMJ of a 15-year-old girl
(case 9) with improved bone condition: discretely flattened and
irregular condyle (blue arrow) at baseline (g) has become smooth
and more rounded (blue arrow) at 2-year follow-up after IAC and
systemic treatment with biologics and MTX (h)
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year follow-up, but no overall significant improvement
was seen.
The improvement in MRI-assessed inflammation is in
accordance with Resnick et al. who found reduced syn-
ovial enhancement in their retrospective study of 29 JIA
patients with 50 TMJs, even if only 18% of their TMJs
experienced complete resolution of synovitis [19]. Most
studies of IACs to the TMJs in patients with JIA report
an MRI improvement of 48–83% regarding inflamma-
tion [16, 17, 27, 28]. However, these studies used differ-
ent definitions of MRI improvement than the MRI
scoring systems used in our study [40, 41].
We found no improvement in the additive damage do-
main comprising condylar flattening, erosions and disc
abnormalities or in the progressive osseous deformity
score. Importantly, increased damage was not found at
the group level, even if 2 of the 10 patients with 2-year
follow-up in our study worsened in the additive damage
domain and 1 of 11 patients worsened in the progressive
score for osseous deformity. Furthermore, two patients
with only 1-year follow-up worsened. We cannot discern
the effect of IACs from the effect of ongoing arthritis,
even if both patients with 2-year follow-up had repeated
IACs once unilaterally. MRI showed persistent inflam-
mation at 2-year follow-up in both these patients. Three
patients improved from baseline to 2-year follow-up and
one patient improved at 1-year follow-up. Furthermore,
another patient who worsened in bone damage between
injection and 2-months follow-up, improved at the 2-
year follow-up.
Stoll et al. [17] found in 15/47 (32%) of the TMJs
injected with IACs, evidence of new-onset erosion and
flattening. Arabshahi et al. [16] also reported post-thera-
peutic progression with bony resorption in three (16%) of
19 TMJs. Ringold et al. [44] reported that 10/15 (67%) of
the patients receiving IACs therapy showed signs of wors-
ening. Lochbuhler et al. [25] reported progressive osseous
deformation in 45 of 66 TMJs in their cohort of children
with JIA and TMJ arthritis receiving repeated injections
(mean 2.4 ± 1.4 IACs per joint, range 0–7).
The additive inflammatory MRI score consists of five
domains. The fact that this additive inflammatory scor-
ing system have scores 0 to 2 (maximum 2) for joint ef-
fusion, joint enhancement and synovial thickening, while
bone marrow edema, bone marrow enhancement scores
maximum 1, place less emphasis on the two latter do-
mains. The same applies to the additive damage MRI
score consisting of three domains, where condylar flat-
tening and erosions score 0 to 2, and disc abnormalities
score maximum 1 if present. It is also unclear how the
progressive system was constructed with regard to rela-
tive weighting of findings. Whether this emphasis is
based on data analyses or constructed for simplicity is
not stated in the publications of the scores.
The progressive inflammation and osseous deformity
scores incorporate several features into one score in a
progressive manner. In one of the four papers [40]
where the system has been presented it is stated that the
most severe change is the deciding feature, however, in
the three others [25, 41, 42] this statement is not in-
cluded. Deciding the most severe change can be challen-
ging, and our interpretation of the system was that a
given score was reliant on fulfillment of the previous
level of pathology. This may have lowered the progres-
sive osseous deformity score if erosions were present
without co-occurrence of flattening, and the progressive
inflammation score if bone marrow oedema was present
without increased synovial enhancement. There was
some variation in the kappa coefficients, both between
right and left side in both systems and between the dif-
ferent variables of the additive system. The best intra-
observer agreement was found for disc abnormalities
and synovial thickening, in the latter with substantial
and almost perfect agreement. The repeatability varied
somewhat more in our study compared to the report by
Tolend et al. [40]. Assessment variations may have influ-
enced the outcome, particularly because of the small
study sample. Further assessment of the precision of the
published scoring systems including inter-rater repeat-
ability is warranted. The scoring systems have not previ-
ously been clinically validated and their ability to detect
change has not been examined.
Whether MRI should be performed to assess the effect
of interventions in TMJ remains unanswered. In Table 4
there is no uniform pattern, but a trend that the MRI
changes in inflammatory scores parallel the clinical im-
provement. Based on our data, clinical experience and
the literature, repeated MRI might be indicated primarily
if clinical symptoms and signs do not improve.
TMJ Arthritis and anterior disc displacement (ADD)
Adolescents with anterior disc displacement (ADD) may
have similar inflammatory changes in the TMJ as adoles-
cents with JIA. According to Kellenberger et al., TMJs
with ADD show a better-preserved and often normal
shape of the glenoid fossa [52]. Even if ADD is not com-
mon in JIA it may occur, representing a differential diag-
nostic challenge with regard to rheumatic or non-
rheumatic disease [53].
IACs techniques
In this study the IACs were performed by arthrocentesis
with steroids with the Alstergren push-and-pull tech-
nique [26] without imaging guidance. This push-and-
pull technique, using a solution of vitamin B12 and
physiological salt water, allows sampling of even very lit-
tle amount of fluid in the TMJ for microbiology and
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immunology assessments together with the local steroid
intervention.
Triamcinolone hexacetonide was mostly used in our
study and is shown to be superior to other corticosteroids
in a randomized controlled trial (RCT) in large joints [54],
only one patient received metylprednisolone acetate [30].
Even if IACs to the TMJs can be safely performed without
radiologic guidance [17, 19], different imaging guiding
techniques are available. Parra and coworkers showed
intraarticular position of the ultrasound (US) - guided
needle, confirmed with a CT -scan in 91% of 127 TMJ in-
jections [23]. In accordance with our clinical experience,
other studies found ultrasound less sensitive for detecting
TMJ synovitis and less feasible to guide TMJ injections
[27, 55]. The use of CT-radiation should be minimized in
growing children. Fritz et al. concluded that real-time
MRI-guided selective injection procedures of the TMJs
are feasible, accurate, and safe when performed on a clin-
ical open-bore 1.5-T MR system [22]. However, special
non-magnetic needles must be used, MRI-guiding is a lo-
gistic challenge, time-consuming and a limited resource in
clinical practice [19, 22].
Side effects
In our study no severe side effects occurred in terms of
infection, bleeding or intraarticular calcifications, even if
a computed tomography (CT) scan may better show cal-
cifications. However, 2 patients had worsening in bone
damage at 2-year follow-up. In addition two patients had
worsened score for bone damage at 1-year follow-up but
have not yet reached 2-year follow-up. However, these
patients had all ongoing inflammation and one of them
a trauma to the mandible that may explain the damage.
Another patient worsened in bone damage between in-
jection and 2-months follow-up but improved at the 2-
year follow-up. Furthermore, three patients improved in
bone damage from baseline to 2-year follow-up and 1
patient improved at 1-year follow-up.
Other studies have reported short-term adverse effects
such as facial swelling, skin atrophy, pain, TMJ stiffness,
chewing dysfunction, fever and TMJ calcifications/ossifi-
cations [16, 17, 23, 44, 45, 56]. A chart review by Ringold
et al. [56] described heterotopic ossification in the TMJ
in children receiving 1–5 TMJ IACs, but the authors
were unable to say whether these ossifications were the
result of the IACs treatment or due to severe, long-
standing TMJ inflammation. Also Lochbuhler et al. [25]
reported severe side effects such as ossifications in the
TMJs after repeated IACs. Rate of osseous deformities
increased from 51% at baseline to 62% at the end of their
study, with progression to severe condylar destruction in
26% of joints including 24% with development of
intraarticular calcifications / ossifications. Importantly,
mandibular growth rate was reduced compared to the
normal age- and sex-matched mean growth rate. In that
study injections were however performed repeatedly. It
is unclear whether the adverse effect of ossifications and
reduced mandibular growth is a problem mainly of re-
peated steroid injections. We could not evaluate the ef-
fects on mandibular growth since the patients were
mostly fully grown at the time the injection was per-
formed. Even if systemic treatment alone seems to im-
prove TMJ arthritis in most children with JIA in a
retrospective study [15], our prospective pilot study may
point to a single steroid injection as a treatment option
for severe symptoms of TMJ-arthritis unresponsive to
systemic treatment in skeletally mature individuals.
Study strengths and limitations
A strength of the present study is the prospective
study design with standardized examination and MRI
protocols in a clinical setting. MRI scoring assess-
ments were performed by two experienced specialists
and masked regarding whether the images were pre-
or post-treatment. In addition, the clinical examiners
used standardized examination protocols and were re-
peatedly calibrated, even if recalibration not necessary
always change the inter-examiner reliability [37]. Our
study sample is comparable to population-based JIA
cohorts and case-control studies regarding gender and
JIA category distribution [7, 8, 17]. A limitation is
that clinical examiners and the patients were not
masked before and after treatment, when assessing
clinical variables such as MIO and pain. It must be
emphasized that the patient group is small, and there-
fore the statistical analyses of the main clinical and
imaging outcomes, and the discrepancies between the
two scoring systems must be interpreted with caution.
We found considerable intra-observer variability for
some domains of the MRI scores, we did not assess
inter-observer variability, and our interpretation of
the scoring systems may differ from that of the ori-
ginal authors.
Conclusion
We found that a single IAC in JIA-patients with TMJ
arthritis may reduce MRI-assessed inflammation, and
improve mouth-opening capacity minimally. At the 2-
months follow-up the pain-index score had improved in
6/11 patients but the change in pain-index score did not
reach significance. Condylar bone damage was mostly
stable but worsened during 2-year follow-up in two pa-
tients with repeated IACs and improved in 3 patients
but no overall significant improvement was seen. There
were no severe side effects. This is the first prospective
clinical study using two recently published MRI scoring
systems. However, further and larger studies are needed
Frid et al. Pediatric Rheumatology           (2020) 18:75 Page 13 of 16
to verify our findings, elaborate on the clinical validity
and adjust the scoring systems where needed. The com-
bined effects of naturally fluctuating JIA disease activity,
systemic medication changes, and TMJ lavage versus
IACs must be considered in the assessment of the
present findings. Further prospective clinical studies on
adolescents with an age not critical for mandibular
growth retardation due to steroid injection, including a
control group, are needed in order to fully elucidate the
effect of IACs on TMJ arthritis.
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